Search Result

Results for "

KDM Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Antibiotic (3) Apoptosis (10) Bacterial (3) Caspase (1) CDK (2) CMV (1) COX (1) Deubiquitinase (3) DNA/RNA Synthesis (1) Environmental Pollutants (1) Estrogen Receptor/ERR (1) Fat Mass and Obesity-associated Protein (FTO) (1) Ferroptosis (2) HCV (2) Histone Demethylase (100) Histone Methyltransferase (1) HSV (1) Isotope-Labeled Compounds (2) MMP (2) mTOR (2) Notch (2) PI3K (2) PROTACs (1) Reference Standards (14) SARS-CoV (2) TGF-beta/Smad (4) Wnt (2) β-catenin (4)
By Research Areas:	Cancer (94) Cardiovascular Disease (5) Endocrinology (2) Infection (5) Inflammation/Immunology (6) Metabolic Disease (2) Neurological Disease (4)

By Targets:

Akt (2)

Antibiotic (3)

Apoptosis (10)

Bacterial (3)

Caspase (1)

CDK (2)

CMV (1)

COX (1)

Deubiquitinase (3)

DNA/RNA Synthesis (1)

Environmental Pollutants (1)

Estrogen Receptor/ERR (1)

Fat Mass and Obesity-associated Protein (FTO) (1)

Ferroptosis (2)

HCV (2)

Histone Demethylase (100)

Histone Methyltransferase (1)

HSV (1)

Isotope-Labeled Compounds (2)

MMP (2)

mTOR (2)

Notch (2)

PI3K (2)

PROTACs (1)

Reference Standards (14)

SARS-CoV (2)

TGF-beta/Smad (4)

Wnt (2)

β-catenin (4)

By Research Areas:

Cancer (94)

Cardiovascular Disease (5)

Endocrinology (2)

Infection (5)

Inflammation/Immunology (6)

Metabolic Disease (2)

Neurological Disease (4)

103

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

Targets Recommended: Serpin

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-15648B

GSK-J4 Maximum Cited Publications 55 Publications Verification	Histone Demethylase Apoptosis	Cancer
GSK-J4 is a potent dual inhibitor of H3K27me3/me2-demethylases *JMJD3/KDM6B* and *UTX/KDM6A* with IC₅₀s of 8.6 and 6.6 μM, respectively. GSK-J4 inhibits LPS-induced TNF-α production in human primary macrophages with an IC₅₀ of 9 μM. GSK J4 is a cell permeable proagent of GSK-J1 . GSK-J4 induces endoplasmic reticulum stress-related apoptosis .

HY-B0568

Deferiprone 45+ Cited Publications	Ferroptosis HCV Apoptosis COX Histone Demethylase	Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone can inhibit KDM. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study .

HY-12304

IOX1 10+ Cited Publications	Histone Demethylase	Cancer
IOX1, a chemical probe, is a potent broad‐spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases. IOX1 inhibits KDM4C, KDM4E, KDM2A, KDM3A and KDM6B with IC₅₀ values of 0.6 μM, 2.3 μM, 1.8 μM, 0.1 μM and 1.4 μM, respectively . IOX1 also inhibits ALKBH5 .

HY-13643

Daminozide 3 Publications Verification	Environmental Pollutants Histone Demethylase	Cancer
Daminozide, a plant growth regulator, is a selective inhibitor of the human KDM2/7 histone demethylases, with IC₅₀s of 0.55, 1.5 and 2.1 μM for PHF8, *KDM2A, and KIAA1718, respectively. Daminozide has >100-fold selectivity for KDM*2/7 subfamily versus other demethylase subfamily members tested .

HY-100421

CPI-455 10+ Cited Publications	Histone Demethylase	Cancer
CPI-455 is a specific, pan-KDM5 inhibitor with an IC₅₀ of 10 nM for KDM5A. CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .

HY-120400

KDM5-C70 5+ Cited Publications	Histone Demethylase	Cancer
KDM5-C70 is an ethyl ester derivative of KDM5-C49 and a potent, cell-permeable and pan-KDM5 histone demethylase inhibitor. KDM5-C70 has an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K4me3 levels .

HY-15648F

GSK-J4 hydrochloride Maximum Cited Publications 55 Publications Verification	Histone Demethylase	Cancer
GSK-J4 hydrochloride is a potent dual inhibitor of H3K27me3/me2-demethylases *JMJD3/KDM6B* and *UTX/KDM6A* with IC₅₀s of 8.6 and 6.6 μM, respectively. GSK-J4 hydrochloride inhibits LPS-induced TNF-α production in human primary macrophages with an IC₅₀ of 9 μM. GSK-J4 hydrochloride is a cell permeable proagent of GSK-J1 .

HY-104048

QC6352 10+ Cited Publications	Histone Demethylase	Cancer
QC6352 is an orally active *KDM4* inhibitor with anti-tumor and anti-proliferative activity. QC6352 has in vivo inhibitory effects on PDX models of breast and colon cancer and reduces the number of chemoresistant cell populations. QC6352 inhibits *KDM4* different isoforms with IC₅₀s of 104 nM (KDM4A), 56 nM (KDM4B), 35 nM (KDM4C), and 104 nM (KDM4D), respectively. QC6352 has moderate inhibitory activity against *KDM5* with an IC₅₀ of 750 nM (KDM5B) .

HY-15648

GSK-J1 15+ Cited Publications	Histone Demethylase	Cancer
GSK-J1, a chemical probe, is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and *UTX/KDM6A, with IC₅₀* of 60 nM towards KDM6B.

HY-12782T

Iadademstat dihydrochloride 5+ Cited Publications ORY-1001 dihydrochloride; RG6016 dihydrochloride; RO 7051790 dihydrochloride	Histone Demethylase	Cancer
Iadademstat (ORY-1001) dihydrochloride is a selective irreversible lysine (K)-specific demethylase 1A (KDM1A/LSD1) inhibitor.

HY-148807

Zavondemstat QC8222 free base; TACH 101 free base	Histone Demethylase Apoptosis	Cancer
Zavondemstat (QC8222 free base; TACH 101 free base) is an orally active pan-KDM4 inhibitor, with a IC₅₀ ≤ 0.08 μM against human KDM4A-D and a Kᵢ of 0.52 μM against human KDM4C. Zavondemstat induces cell apoptosis, causes S-phase cell cycle arrest, reduces the population of tumor-initiating cells and inhibits cancer cell proliferation. Zavondemstat suppresses tumor growth and induces tumor regression in mouse xenograft models. Zavondemstat can be used for the research of various cancers including colorectal cancer, esophageal squamous cell carcinoma and triple-negative breast cancer .

HY-18632

GSK2879552 15+ Cited Publications	Histone Demethylase	Cancer
GSK2879552 an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/ KDM1A), with potential antineoplastic activity .

HY-107573

KDM2/7-IN-1 1 Publications Verification	Histone Demethylase	Cancer
KDM2/7-IN-1 (TC-E 5002) is a selective histone demethylase *KDM2/7* subfamily inhibitor (IC₅₀ values are 0.2, 1.2, 6.8, 55, 83, >100 and >120 μM for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, KDM6A and KDM4A respectively). KDM2/7-IN-1 inhibits growth of HeLa and KYSE-150 cancer cells in vitro .

HY-116761

GSK467 5 Publications Verification	Histone Demethylase	Cancer
GSK467 is a cell penetrant and selective *KDM5B* (JARID1B or PLU1) inhibitor with a K_i of 10 nM and an IC₅₀ of 26 nM. GSK467 shows 180-fold selectivity for KDM4C and no measurable inhibitory effects toward KDM6 or other Jumonji family members .

HY-100760

Toxoflavin 5+ Cited Publications Xanthothricin; Toxoflavine; PKF-118-310	β-catenin Bacterial Antibiotic Histone Demethylase	Infection Cancer
Toxoflavin (Xanthothricin) is an antagonist of transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of *KDM4A*, with antitumor and antibiotic activity .

HY-109117

Iadademstat 5+ Cited Publications ORY-1001	Histone Demethylase Apoptosis	Cancer
Iadademstat (ORY-1001) is a highly potent, orally active and selective LSD1 (KDM1A) inhibitor with antileukemic activity. Iadademstat can be used for relapsed or refractory acute myeloid leukemia research .

HY-12725

ML324 5+ Cited Publications	Histone Demethylase HSV CMV	Cancer
ML324 is a potent JMJD2 demethylase inhibitor with antiviral activity. ML324 also exhibits inhibition for the histone demethylase *KDM4B, with an IC₅₀* of 4.9 μM. ML324 has potent anti-viral activity against both herpes simplex virus (HSV) and human cytomegalovirus (hCMV) infection via inhibition viral IE gene expression .

HY-18632A

GSK2879552 dihydrochloride 15+ Cited Publications	Histone Demethylase	Cancer
GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/KDM1A), with potential antineoplastic activity .

HY-100744

AS8351 1 Publications Verification NSC51355	Histone Demethylase	Cardiovascular Disease
AS8351 (NSC51355) is a *KDM5B* inhibitor, which can induce and sustain active chromatin marks to facilitate the induction of cardiomyocyte-like cells .

HY-103713

Seclidemstat 10+ Cited Publications SP-2577	Histone Demethylase	Cancer
Seclidemstat is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (K_i=31 nM, IC₅₀=13 nM). Seclidemstat promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat can be used for the research of Ewing Sarcoma .

HY-102047B

KDOAM-25 citrate 5+ Cited Publications	Histone Demethylase	Cancer
KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 citrate increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells .

HY-19612A

DDP-38003 dihydrochloride 1 Publications Verification	Histone Demethylase	Cancer
DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC₅₀ of 84 nM .

HY-100421A

CPI-455 hydrochloride 10+ Cited Publications	Histone Demethylase	Cancer
CPI-455 hydrochloride is a specific, pan-KDM5 inhibitor with an IC₅₀ of 10 nM for KDM5A. CPI-455 hydrochloride mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .

HY-139348

PFI-90 1 Publications Verification	Histone Demethylase Apoptosis	Cancer
PFI-90 is a selective inhibitor of histone demethylase *(KDM3B)* that inhibits PAX3-FOXO1 action. PFI-90 induces apoptosis and myogenic differentiation, resulting in the cell death increased. PFI-90 has the potential for the antitumor activity. (patent WO2021101929A1).

HY-132896

KDM4-IN-3	Histone Demethylase	Cancer
KDM4-IN-3 (Compound 15) is a *KDM4* inhibitor (IC₅₀ = 871 nM) that exhibits improved potency in biochemical assays. KDM4-IN-3 is cell-permeable and kills prostate cancer cells at low micro molar concentrations. KDM4-IN-3 inhibits growth of prostate cancer cell lines and increases the H3K9me3 abundance. KDM4-IN-3 can be studied in research for prostate cancer .

HY-100422

KDM5-IN-1 2 Publications Verification	Histone Demethylase	Cancer
KDM5-IN-1 is a potent, selective and orally bioavailable *KDM5* inhibitor with an IC₅₀ of 15.1 nM.

HY-100014

KDM5A-IN-1 4 Publications Verification	Histone Demethylase	Cancer
KDM5A-IN-1 is a potent, orally bioavailable pan-histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 45 nM, 56 nM and 55 nM for *KDM5A, KDM5B* and *KDM5C, respectively, and with an EC₅₀* value of 960 nM for PC9 H3K4Me3. KDM5A-IN-1 is significantly less potent against other *KDM5B* enzymes (1A, 2B, 3B, 4C, 6A, 7B) .

HY-101799

NCGC00244536 2 Publications Verification KDM4B Inhibitor B3	Histone Demethylase	Cancer
NCGC00244536 is a potent *KDM4B* inhibitor with an IC₅₀ of 10 nM.

HY-15648A

GSK-J2 4 Publications Verification	Histone Demethylase	Cancer
GSK-J2 is an isomer of GSK-J1 that does not have any specific activity. GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A.

HY-101451

PBIT 3 Publications Verification	Histone Demethylase	Cancer
PBIT is a specific inhibitor of the Jumonji AT-rich Interactive Domain 1 (JARID1) enzymes. PBIT inhibits JARID1B (KDM5B or PLU1) histone demethylase with an IC₅₀ of about 3 μM . PBIT also inhibits JARID1A and JARID1C with IC₅₀s of 6 μM and 4.9 μM, respectively .

HY-100624

Ryuvidine	CDK DNA/RNA Synthesis Histone Demethylase Histone Methyltransferase	Inflammation/Immunology Cancer
Ryuvidine is a potent inhibitor of SET domain-containing protein 8(SETD8) with an IC₅₀ of 0.5 µM and suppresses monomethylation of H₄K₂₀. Ryuvidine also inhibits CDK4 with an IC₅₀ of 6.0 μM. Ryuvidine also inhibits *KDM5A* and blocks DNA synthesis. Ryuvidine has anticancer activity against tumors such as breast cancer. Ryuvidine improves arthritis .

HY-119397A

KDM5-C49 hydrochloride 1 Publications Verification KDOAM-20 hydrochloride	Histone Demethylase	Cancer
KDM5-C49 (KDOAM-20) hydrochloride is a potent and selective inhibitor of KDM5 demethylases, with IC₅₀s of 40 nM, 160 nM, and 100 nM for *KDM5A, KDM5B, and KDM5C enzymes, respectively. KDM*5-C49 hydrochloride can be used for the research of cancer .

HY-139561

KDM2B-IN-2	Histone Demethylase	Inflammation/Immunology Cancer
KDM2B-IN-2, a potent histone demethylase (kdm2b) inhibitor with an IC₅₀ of 0.021 μM in a KDM2B TR-FRET assay. KDM2B-IN-2 can be used for hyperproliferative diseases research .

HY-110154

NSC636819	Histone Demethylase	Cancer
NSC636819 is a competitive and selective inhibitor of *KDM4A/KDM4B. KDM4A/KDM*4B are potential progression factors for prostate cancer. NSC636819 has the potential for the research of cancer diseases, especially prostate cancer .

HY-139601

KDM2B-IN-4	Histone Demethylase	Cancer
KDM2B-IN-4 (Compound 182b) is a histone demethylase KDM2B inhibitor with an IC₅₀ of 1.12 nM. KDM2B-IN-4 can be used for the research of hyperproliferative diseases such as cancers .

HY-146148

KDM4C-IN-1 2 Publications Verification	Histone Demethylase	Cancer
KDM4C-IN-1 (Compound 4d) is a potent *KDM4C* inhibitor with an IC₅₀ of 8 nM. KDM4C-IN-1 inhibits the growth of HepG2 and A549 cells with IC₅₀s of 0.8 µM and 1.1 µM, respectively .

HY-101928

KDM4D-IN-1 2 Publications Verification	Histone Demethylase	Cancer
KDM4D-IN-1 is a new histone lysine demethylase 4D (KDM4D) inhibitor with an IC₅₀ value of 0.41±0.03 μM.

HY-108706

KDM2A/7A-IN-1	Histone Demethylase	Cancer
KDM2A/7A-IN-1 is a first-in-class, selective and cell-permeable inhibitor of histone lysine demethylases KDM2A/7A, with an IC₅₀ of 0.16 μM for KDM2A, exhibits 75 fold selevtivity over other JmjC lysine demethylases, and is inactive on methyl transferases, and histone acetyl transferases .

HY-100764

YUKA1 1 Publications Verification	Histone Demethylase	Cancer
YUKA1 is a potent and cell permeable Lysine demethylase 5A (KDM5A) inhibitor, with an IC₅₀ of 2.66 μM. YUKA1 has less inhibitory active on KDM5C (IC₅₀ = 7.12 μM) and is inactive on KDM5B, KDM6A or KDM6B. YUKA1 can increase H3K4me3 levels and inhibit cell proliferation. YUKA1 can be used for the research of cancer, such as lung and breast cancers .

HY-138830

TAK-418 2 Publications Verification	Histone Demethylase	Neurological Disease
TAK-418 is a selective, orally active LSD1 (KDM1A) enzyme inhibitor with an IC₅₀ of 2.9 nM. TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models .

HY-103713A

Seclidemstat mesylate 10+ Cited Publications SP-2577 mesylate	Histone Demethylase	Cancer
Seclidemstat (SP-2577) mesylate is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (K_i=31 nM, IC₅₀=13 nM). Seclidemstat mesylate promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat mesylate can be used for the research of Ewing Sarcoma .

HY-129079

TFMB-(R)-2-HG 3 Publications Verification	Estrogen Receptor/ERR Histone Demethylase Fat Mass and Obesity-associated Protein (FTO)	Cancer
TFMB-(R)-2-HG is a cell membrane-permeable (R)-2-HG and acute myeloid leukemia (AML) oncogenic factor. TFMB-(R)-2-HG competitively inhibits α-ketoglutarate-dependent dioxygenases such as *KDM2B* and FTO. TFMB-(R)-2-HG impairs cell differentiation in response to Estrogen withdrawal. TFMB-(R)-2-HG is used in acute myeloid leukemia and glioma research .

HY-139560

KDM2B-IN-1	Histone Demethylase	Inflammation/Immunology Cancer
KDM2B-IN-1 (example 32) is a histone demethylase (kdm2b) inhibitor with an IC₅₀ of 0.016 nM. KDM2B-IN-1 can be used for hyperproliferative diseases research .

HY-149091

KDM5B-IN-4	Histone Demethylase	Cancer
KDM5B-IN-4 (compound 11ad) is a lysine demethylase 5B (KDM5B) inhibitor with an IC₅₀ of 0.025 μM KDM5B-IN-4 increases substrate H3K4me1/2/3 level by inhibiting *KDM5B* in PC-3 cells. KDM5B-IN-4 downregulates PI3K/AKT. KDM5B-IN-4 reduces tumor volume in mice and shows less toxic to organs .

HY-151483

TK-129	Wnt Histone Demethylase	Cardiovascular Disease
TK-129 is an orally active, low-toxicity, potent KDM5B inhibitor (with high affinity; IC₅₀=44 nM). TK-129 exerts cardioprotective effects by inhibiting *KDM5B* and blocking the *KDM5B*-associated Wnt pathway. TK-129 reduces ang II-induced activation of cardiac fibroblasts in vitro and reduces isoprenaline-induced myocardial remodelling and fibrosis in vivo. TK-129 can be used in studies of cardiovascular disease .

HY-138691A

JQKD82 trihydrochloride JADA82 trihydrochloride; PCK82 trihydrochloride	Histone Demethylase	Cancer
JQKD82 (JADA82) trihydrochloride is a cell-permeable and selective *KDM5* inhibitor. JQKD82 trihydrochloride increases H3K4me3 and can be used for the research of multiple myeloma .

HY-N6896

Isoviolanthin 1 Publications Verification	TGF-beta/Smad PI3K Akt mTOR MMP Histone Demethylase	Endocrinology Cancer
Isoviolanthin is a flavonoid glycoside. Isoviolanthin can be extracted from Dendrobium officinale. Isoviolanthin has a strong affinity for binding to *KDM6B, CHAC2, ESCO2, and IPO4. Isoviolanthin decreases MMP-2* and MMP-9. Isoviolanthin inhibits TGF-β/Smad and PI3K/Akt/mTOR signaling pathways. Isoviolanthin increases Fhl3 expression. Isoviolanthin has cytoprotective effects. Isoviolanthin has anticancer activity against hepatocellular carcinoma .

HY-102047

KDOAM-25	Histone Demethylase	Cancer
KDOAM-25 is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells .

HY-15648D

GSK-J1 lithium salt 15+ Cited Publications	Histone Demethylase	Cancer
GSK-J1 lithium salt is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and *UTX/KDM6A, with IC₅₀* of 60 nM towards KDM6B.

HY-168593

PROTAC KDM3 degrader-1	β-catenin PROTACs Wnt Histone Demethylase	Cancer
PROTAC KDM3 degrader-1 (Compound 4) is a CRBN-recruiting PROTAC designed based on the IOX1 (HY-12304) scaffold. PROTAC KDM3 degrader-1 selectively degrades the *KDM3A* and *KDM3B* proteins, thereby inhibiting the Wnt/β-catenin signaling pathway. PROTAC KDM3 degrader-1 significantly suppresses the self-renewal capacity of colorectal cancer stem cells and inhibits the growth of colorectal cancer tumors. PROTAC KDM3 degrader-1 is suitable for research on colorectal cancer (Target protein ligand (Pink): HY-12304; linker (Black): HY-22335; Conjugate of E3 ligase ligand and linker: HY-112599; E3 ligase (Blue): HY-41547) .

Cat. No.	상품명	Type

HY-138794G

XL177A

Fluorescent Dyes

XL177A GMP is XL177A (HY-138794) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. XL177A is a covalent USP7 inhibitor that blocks the deubiquitinase activity of USP7. XL177A destabilizes non-canonical PRC1 complexes or KDM6A and reduces chromatin deposition of H2AK119Ub, thereby relieving the repression of neuronal differentiation programs. Meanwhile, XL177A also regulates the ELOF1-UVSSA-USP7-nuclear β-catenin axis, decreasing the transcription levels of related proteins and the accumulation of nuclear β-catenin. XL177A exerts antiviral effects by reducing the expression levels of coronavirus receptors, and exhibits inhibitory activity against APC-mutated colorectal cancer cells, neuroblastoma, and coronaviruses including SARS-CoV-2 variants. XL177A is mainly used in studies related to colorectal cancer, neuroblastoma, and coronavirus infections .

Cat. No.	상품명	Type

HY-138794G

XL177A

Biochemical Assay Reagents

Cat. No.	상품명	Category	Target	Chemical Structure

HY-13643

Daminozide 3 Publications Verification	Classification of Application Fields Ketones, Aldehydes, Acids Dendranthema morifolium (Ramat.) Tzvel. Plants Compositae Disease Research Fields Biological Pesticide Research Source Classification Cancer Agricultural Research	Environmental Pollutants Histone Demethylase
Daminozide, a plant growth regulator, is a selective inhibitor of the human KDM2/7 histone demethylases, with IC₅₀s of 0.55, 1.5 and 2.1 μM for PHF8, *KDM2A, and KIAA1718, respectively. Daminozide has >100-fold selectivity for KDM*2/7 subfamily versus other demethylase subfamily members tested .

HY-N6896

Isoviolanthin 1 Publications Verification	Flavonoids other families Classification of Application Fields Flavones Phenols Polyphenols Plants Disease Research Fields Source Classification Cancer	TGF-beta/Smad PI3K Akt mTOR MMP Histone Demethylase
Isoviolanthin is a flavonoid glycoside. Isoviolanthin can be extracted from Dendrobium officinale. Isoviolanthin has a strong affinity for binding to *KDM6B, CHAC2, ESCO2, and IPO4. Isoviolanthin decreases MMP-2* and MMP-9. Isoviolanthin inhibits TGF-β/Smad and PI3K/Akt/mTOR signaling pathways. Isoviolanthin increases Fhl3 expression. Isoviolanthin has cytoprotective effects. Isoviolanthin has anticancer activity against hepatocellular carcinoma .

HY-13643R

Daminozide (Standard)	Ketones, Aldehydes, Acids Dendranthema morifolium (Ramat.) Tzvel. Plants Compositae Source Classification	Reference Standards Histone Demethylase
Daminozide (Standard) is the analytical standard of Daminozide. This product is intended for research and analytical applications. Daminozide, a plant growth regulator, is a selective inhibitor of the human KDM2/7 histone demethylases, with IC50s of 0.55, 1.5 and 2.1 μM for PHF8, KDM2A, and KIAA1718, respectively. Daminozide has >100-fold selectivity for KDM2/7 subfamily versus other demethylase subfamily members tested .

HY-N6896R

Isoviolanthin (Standard)	Structural Classification Flavonoids other families Flavones Phenols Polyphenols Plants Source Classification	Reference Standards TGF-beta/Smad PI3K Akt mTOR MMP Histone Demethylase
Isoviolanthin (Standard) is the analytical standard of Isoviolanthin (HY-N6896). This product is intended for research and analytical applications. Isoviolanthin is a flavonoid glycoside. Isoviolanthin can be extracted from Dendrobium officinale. Isoviolanthin has a strong affinity for binding to *KDM6B, CHAC2, ESCO2, and IPO4. Isoviolanthin decreases MMP-2* and MMP-9. Isoviolanthin inhibits TGF-β/Smad and PI3K/Akt/mTOR signaling pathways. Isoviolanthin increases Fhl3 expression. Isoviolanthin has cytoprotective effects. Isoviolanthin has anticancer activity against hepatocellular carcinoma .

Cat. No.	상품명	Chemical Structure

HY-100760S

Toxoflavin-13C4
Toxoflavin- ¹³C₄ is the ¹³C-labeled Toxoflavin. Toxoflavin (Xanthothricin) is an antagonist of transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of KDM4A, with antitumor activity . Antibiotic properties.

HY-B0568S

Deferiprone-d3

Deferiprone-d₃ is the deuterium labeled Deferiprone (HY-B0568). Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone can inhibit KDM. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study .

Targets Recommended: Serpin

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-138794G

XL177A	Deubiquitinase SARS-CoV Histone Demethylase	Cancer
XL177A GMP is XL177A (HY-138794) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. XL177A is a covalent USP7 inhibitor that blocks the deubiquitinase activity of USP7. XL177A destabilizes non-canonical PRC1 complexes or *KDM6A* and reduces chromatin deposition of H2AK119Ub, thereby relieving the repression of neuronal differentiation programs. Meanwhile, XL177A also regulates the ELOF1-UVSSA-USP7-nuclear β-catenin axis, decreasing the transcription levels of related proteins and the accumulation of nuclear β-catenin. XL177A exerts antiviral effects by reducing the expression levels of coronavirus receptors, and exhibits inhibitory activity against APC-mutated colorectal cancer cells, neuroblastoma, and coronaviruses including SARS-CoV-2 variants. XL177A is mainly used in studies related to colorectal cancer, neuroblastoma, and coronavirus infections .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

KDM Inhibitors

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

GMP Molecules

Natural
Products